TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03502187

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Management (PCM)
Description: All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Management (PCM)
Description: All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.
Study: NCT02514941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastroduodenoscopy with biopsy
Description: Gastroduodenoscopy with biopsy of the lower duodenum before the first pharmacokinetic study period
Study: NCT05693402

Intervention type: PROCEDURE
Intervention: opioid anesthesia
Description: opioid-free general anesthesia vs non opioid-free general anesthesia
Study: NCT02514941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrojejunoscopy with biopsy
Description: Gastrojejunoscopy with biopsy of the jejunum about one year after proximal Roux-en-Y gastric bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal Roux-en-Y gastric bypass
Description: sampling of a tissue specimen from the jejunum during the operation
Study: NCT03380754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricia preOp
Description: A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nestle Splash Lemon Flavor Water (Placebo)
Description: Placebo control drink. PURIFIED WATER, NATURAL FLAVORS, CITRIC ACID, SODIUM POLYPHOSPHATE, POTASSIUM SORBATE (PRESERVE FRESHNESS), POTASSIUM BENZOATE (PRESERVE FRESHNESS), SUCRALOSE, ACESULFAME POTASSIUM, CALCIUM DISODIUM EDTA, MAGNESIUM SULFATE.
Study: NCT01364194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
Study: NCT00436540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate 0.05% Spray
Description: Apply to affected areas twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate 0.05% Foam
Description: Apply to affected areas twice daily
Study: NCT00357591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Aortic Flow Augmentation
Description: 1.0-1.5 lpm augmented blood flow
Study: NCT04062500

Intervention type: OTHER
Intervention: Mortality and Rehospitalization rate
Description: Mortality and Re-hospitalization of acute decompensated heart failure
Study: NCT01716962

Intervention type: OTHER
Intervention: Infusion of 6% tetrastarch for a total of 500 ml
Study: NCT03956719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem cells
Description: Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal liposuction
Description: 50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells
Study: NCT02663726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 10 weekly 75-min sessions of specialised yoga

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written advice
Description: Written advice about physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written advice
Description: Written advice about physical activity
Study: NCT02913313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986207
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986207
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986207
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986207
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986207
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986207
Description: Specified dose on specified days
Study: NCT02257762

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn-soy blend ++ (CSB++)
Description: Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
Study: NCT02913313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT04080206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 188-0551 Spray
Description: Applied topically twice daily for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD
Description: Applied topically twice daily for two weeks
Study: NCT03742427

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonography
Description: optic nerve sheath diameter measurement will be done by ultrasonography on both eyes
Study: NCT04119570

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CKD Report Card
Description: The CKD Report Card is a handout based on a NKDEP Educational Sheet that includes basic information about kidney disease and spaces where patient can record information about their own kidney disease
Study: NCT04298762

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No peer comparison email
Description: The comparison group received no email communication on their cancer stage documentation activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer comparison email
Description: The intervention group received three separate emails with individualized data on their cancer stage documentation activity in the previous 1-3 months. The email described the number and percent of attributed patients for whom cancer stage was documented, and included a figure showing their staging documentation rate compared to their peers.
Study: NCT01555229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent subglottic secretion drainage
Description: Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
Study: NCT02257762

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sprinkles
Description: Multiple micronutrient powder packaged in sachet.
Study: NCT01555229

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous subglottic secretion drainage
Description: Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
Study: NCT01765894

Intervention type: OTHER
Intervention: 45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.

Intervention type: OTHER
Intervention: 45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.

Intervention type: OTHER
Intervention: 45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.
Study: NCT00995254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHI counseling
Description: The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
Study: NCT02798926

Intervention type: DEVICE
Intervention: polyethylene bag
Description: The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
Study: NCT01091636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: 41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
Study: NCT04765605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-Tbranch Stent Graft System
Description: The single-embedded branch thoracic aorta stent graft system consists of the thoracic aorta stent graft system and the branch stent system. The main chest embedded stent graft system consists of the main chest embedded stent graft and its system conveyor, and the branch stent system consists of branch stents and its conveyor. The main chest embedded stent graft and the branch stent are pre-installed in the conveyor
Study: NCT02296060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 minutes walking test
Study: NCT03227367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: other : PRF
Description: mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination

Intervention type: OTHER
Group type: OTHER
Intervention: other : PRF
Description: mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
Study: NCT00940004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell vaccination
Description: Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous dendritic cell vaccination
Description: Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
Study: NCT02024984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle.
Study: NCT04106154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinesiology Support
Description: 12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
Study: NCT03973476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone care support by midwife
Description: Mothers can call the midwife's telephone every working day from 8 a.m. to 8 p.m.
Study: NCT01953952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo transoral eHNS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01545960

Intervention type: OTHER
Intervention: not applicable in this study
Description: No actual interventions will be administered for this study.
Study: NCT02073487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: antibody-drug conjugate of trastuzumab and emtansine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: anti-Her2 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Dual tyrosine kinase inhibitor (HER2 and EGFR)
Study: NCT00680719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBFT /HIV prevention
Description: Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
Study: NCT02073487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: chemotherapy - microtubule inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: anti-HER2 monoclonal antibody
Study: NCT04244344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fall prevention measures
Description: High fall risk signage, information sheet, High fall risk bracelet, verbal instructions
Study: NCT02660125

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratch injury
Description: midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
Study: NCT00537433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictogram
Description: The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.~Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home.
Study: NCT00680719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBFT
Description: Integrated Behavioral and Family Therapy (IBFT).
Study: NCT03593473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
Study: NCT01710410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial Direct Current Stimulation
Description: Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial Direct Current Stimulation
Description: Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
Study: NCT02395991

Intervention type: DRUG
Intervention: gadoxetic acid
Description: standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration

Intervention type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.~precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.
Study: NCT01710410

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial Direct Current Stimulation
Description: Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
Study: NCT02735889

Intervention type: OTHER
Group type: OTHER
Intervention: No Carbonation
Description: 500 ml of beverage consisting of water + 10% glucose and no carbonation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carbonation
Description: 500 ml of beverage consisting of water + 10% glucose and low carbonation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carbonation
Description: 500 ml of beverage consisting of water + 10% glucose and high carbonation
Study: NCT00918996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of Bladder Flap Creation
Description: Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
Study: NCT04200040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OrienX010 injection
Description: OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine (DTIC)
Description: Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
Study: NCT01718977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Weight Supported Treadmill Training
Description: BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.